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Pyrimidine Pathway-Dependent and -Independent Functions of the
Toxoplasma gondii Mitochondrial Dihydroorotate Dehydrogenase
Miryam Andrea Hortua Triana,a* Daniela Cajiao Herrera,b Barbara H. Zimmermann,b Barbara A. Fox,a David J. Bzika
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USAa; Departamento de Ciencias Biológicas,
Universidad de los Andes, Bogotá, Colombiab
Dihydroorotate dehydrogenase (DHODH) mediates the fourth step of de novo pyrimidine biosynthesis and is a proven drug
target for inducing immunosuppression in therapy of human disease as well as a rapidly emerging drug target for treatment of
malaria. In Toxoplasma gondii, disruption of the first, fifth, or sixth step of de novo pyrimidine biosynthesis induced uracil aux-
otrophy. However, previous attempts to generate uracil auxotrophy by genetically deleting the mitochondrion-associated
DHODH of T. gondii (TgDHODH) failed. To further address the essentiality of TgDHODH, mutant gene alleles deficient in
TgDHODH activity were designed to ablate the enzyme activity. Replacement of the endogenous DHODH gene with catalytically
deficient DHODH gene alleles induced uracil auxotrophy. Catalytically deficient TgDHODH localized to the mitochondria, and
parasites retained mitochondrial membrane potential. These results show that TgDHODH is essential for the synthesis of py-
rimidines and suggest that TgDHODH is required for a second essential function independent of its role in pyrimidine
biosynthesis.
Toxoplasma gondii is an obligate intracellular parasite with anextremely broad host range (1). Primary infection during
pregnancy can cause fetal death or severe congenital disease (2).
Reactivated infection causes recurrent ocular toxoplasmosis (3),
and during AIDS or immune suppression, reactivation of chronic
infection causes severe and difficult-to-treat toxoplasmic enceph-
alitis (4). Current drug treatment regimens for toxoplasmosis are
poorly tolerated and have limited efficacy on chronic cyst stages
(4, 5); thus, alternative therapeutic options are urgently needed.
Many of the clinically relevant drugs used to treat Toxoplasma
infections, as well as related Plasmodium parasites that cause ma-
laria, directly or indirectly target pyrimidine metabolism (6). The
de novo pyrimidine biosynthetic pathway possesses several poten-
tial new drug targets (7). The fourth step of the pyrimidine bio-
synthetic pathway, mediated by dihydroorotate dehydrogenase
(DHODH), is of interest because current therapeutic treatments
target the human DHODH and Plasmodium parasites lack the
ability to salvage pyrimidines; thus, the de novo pyrimidine
pathway is the only source of pyrimidines for Plasmodium cell
growth (6, 8, 9). Recently, the triazolopyrimidine DMS265 was
advanced to clinical development as an antimalarial drug based on
important characteristics such as extended bloodstream half-life,
high selectivity toward the parasite enzyme, and excellent tolera-
bility (10). Recently described triazolopyrimidine analogs exhibit
even greater selectivity and efficiency against Plasmodium
DHODH than does DSM265 (11).
In contrast to Plasmodium species, T. gondii has the ability not
only to synthesize pyrimidines de novo (12) but also to salvage
pyrimidines by first converting pyrimidine nucleosides to uracil,
which is incorporated into the crucial pyrimidine pool as UMP by
a uracil phophoribosyltransferase activity (13, 14), though this
salvage pathway is not essential for acute (14, 15) or chronic (16)
infection. Genetic deletion of the first, fifth, or sixth step of the
pyrimidine biosynthetic pathway in T. gondii induced severe ura-
cil auxotrophy, virulence attenuation, and undetectable chronic
infection (16–19). The T. gondii DHODH (TgDHODH), like the
Plasmodium and human DHODH enzymes, resembles the family
2 DHODH enzymes (20, 21). Family 2 DHODH is monomeric
and membrane associated and localizes to the inner mitochon-
drial membrane in both Toxoplasma and Plasmodium (22, 23).
Family 2 DHODHs are coupled to the respiratory chain through
ubiquinone-mediated reoxidation of DHODH, and electrons
from oxidation of dihydroorotate enter the respiratory chain (24).
Chemical inhibitors of TgDHODH activity in vitro were previ-
ously identified, and inhibitor profiles and bioinformatic analysis
suggested that the enzyme was a potentially selective target for
chemical inhibition (22). However, previous attempts to geneti-
cally delete the TgDHODH gene to create a uracil-auxotrophic
mutant and to demonstrate the essentiality of this gene and activ-
ity were unsuccessful (22). Here, we examined the essential func-
tions of TgDHODH through the development of catalytically de-
ficient TgDHODH gene alleles. We found that deletion of the
endogenous TgDHODH gene to generate uracil auxotrophy was
feasible only if the endogenous gene was replaced with a catalyti-
cally deficient TgDHODH gene allele. These results suggest that
TgDHODH is essential for two reasons, generation of the essential
pyrimidine pools and another essential role in mitochondrial
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function or physiology that is not directly dependent on the
DHODH enzyme activity.
MATERIALS AND METHODS
Culture conditions and strains. All parasite strains were continuously
maintained in vitro by serial passage in Eagle modified essential medium
supplemented with 1% fetal bovine serum in diploid human foreskin
fibroblasts (HFF) at 36°C (25). Pyrimidine auxotrophs were supple-
mented with uracil (250 M) (26). Targeted genetic manipulation of T.
gondii was performed using the nonhomologous-recombination-defi-
cient type I RH ku80 knockout strain (27).
Transformation, selection, and gene replacement validation. Prior
to transfection, all plasmids were linearized at the 5= end using the unique
PmeI restriction enzyme site incorporated into the targeting plasmids.
Approximately 15 g of plasmid DNA was transfected into T. gondii strain
RH ku80 hxgprt (27) using a model BTX600 electroporator. Selection
for integration of the targeting plasmid was performed in mycophenolic
acid (MPA) (25 g/ml) and xanthine (50 g/ml). TgDHODH mutant
strains were also selected in the presence of uracil supplementation (250
M) (18). Stable MPA-resistant clones were isolated, and genomic DNA
was prepared with a DNA blood minikit (Qiagen) using a Qiacube auto-
mated robotic workstation. PCR products were amplified using a 1:1 mix-
ture of Taq DNA polymerase and Expand long-template polymerase
(Roche).
The PCR validation strategy was designed to measure the following: (i)
PCR1, loss of intron 2 and absence of the endogenous TgDHODH gene,
(ii) PCR2A and PCR2B*, correct integration of the targeting DNA, (iii)
PCR3, loss of intron 11 and absence of the endogenous DHODH gene, (iv)
PCR 4, correct 5= target integration, and (v) PCR5, correct 3= target inte-
gration. DNA primers used to construct plasmids for genetic manipula-
tions and validation of progeny genotypes are shown in Table S1 in the
supplemental material.
Site-directed mutagenesis. The previously reported cDNA (the
pET19b-TgDHODH-VSSM plasmid [22], here designated pET19b-WT)
encoding active wild-type TgDHODH enzyme was used as the template to
build three mutant versions of DHODH. Mutagenesis was performed
with the Stratagene QuikChange XS site-directed mutagenesis kit in order
to mutate both N365 (pET19b-N365A) and N468 (pET19b-N468A) into
an alanine. The N365/N468 double mutant (pET19b-N365A/N468A) was
constructed using the pET19b-N468A expression plasmid. Oligonucleo-
tide primers used to make the DHODH enzymes with single point muta-
tions are listed in Table S1 in the supplemental material. Mutations were
confirmed by DNA sequencing.
Gene-targeting plasmid constructs. Plasmid constructs used for gene
replacement at the TgDHODH gene locus were developed in the yeast
shuttle vector pRS416. Three distinct genetic elements were amplified by
PCR and fused in the correct order using a yeast recombinational cloning
system (28, 29). The first genetic element, corresponding to the 5=
DHODH target flank, was amplified from genomic DNA (1.5 kbp). The
5= DHODH target flank includes exon 1 and intron 1 of endogenous
TgDHODH. The pET19b-WT, pET19b-N468A, pET19b-N468A, and
pET19b-N365A/N468A expression plasmids were used to amplify the sec-
ond genetic element, corresponding to DHODH cDNA (1.2 kbp). The
third genetic element, containing the hypoxanthine guanine phosphori-
bosyl transferase (HXGPRT) minigene cassette and 3= gene flank of the
endogenous TgDHODH gene (2.8 kbp), was amplified from the previ-
ously described pDHOD plasmid (22) using a forward primer that in-
serted the hemagglutinin (HA) tag at the C terminus of TgDHODH.
Oligonucleotide primers used in PCR to construct gene replacement tar-
geting plasmids are listed in Table S1 in the supplemental material. Gene-
targeting plasmids were validated by restriction digest and by DNA se-
quencing to verify 100% homology in gene-targeting flanks.
Pyrimidine starvation assays. PFU assays were used to test pyrimi-
dine starvation. Four 25-cm2 HFF flasks were inoculated with 500 PFU
per strain. Parasites were allowed to invade for 2 h in uracil medium and
were then rinsed with cold phosphate-buffered saline (PBS) to remove
uracil and extracellular parasites. Two flasks were provided with fresh
medium supplemented with uracil, and the remaining two flasks were
incubated in medium lacking uracil to induce pyrimidine starvation. Cul-
tures were incubated undisturbed for 7 days, and then monolayers were
fixed, stained, and photographed.
Protein electrophoresis and immunoblots. SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) was carried out on 1-mm-thick gels, using 4
to 12% gradient NuPAGE precast bis-Tris gels and 1 MOPS (morpho-
linepropanesulfonic acid) SDS running buffer (Life Technologies). Elec-
trophoresis was performed in a Hoefer SE260 small-format vertical elec-
trophoresis system using a constant 160 V until the dye front crossed the
stacking gel and then a constant 200 V until the dye front reached the gel
bottom. Samples for immunoblots were prepared by resuspending a pellet
of 1.5  108 tachyzoites in 40 l lysis buffer containing 2 complete
mini-protease inhibitor cocktail (Roche), 5 mM potassium phosphate
(pH 7.0), 1 mM EDTA, 1 mM dithiothreitol (DTT), and 2% Triton X-100,
and subjecting the solution to five freeze/thaw cycles. Lysates were centri-
fuged at 4°C and 16,000  g for 20 min. Supernatants of lysed parasites
were boiled for 10 min at 90°C in 4 NuPAGE lithium dodecyl sulfate
(LDS) sample buffer (Life Technologies). Total protein concentration in
supernatants of lysates were measured by the bicinchoninic acid (BCA)
protein assay (Pierce) with bovine serum albumin (BSA) as the standard,
using the microplate procedure performed according the manufacturer’s
instructions. Samples were electrotransferred from gels to nitrocellulose
membranes (Millipore) using a Trans-Blot Turbo transfer system (Bio-
Rad) for 50 min at 1.0 A with constant current. The blotted membrane
was blocked with 5% nonfat dry milk in 1 TBS (10 mM Tris-HCl and
150 mM NaCl pH 7.4) containing 0.05% Tween 20 (TBS-T buffer) for 30
min. After washing the membrane 3 times with TBS-T, rat anti-HA
monoclonal antibody (Roche) (100 ng/ml), diluted in TBS-T, was added
and incubated overnight at 4°C. The bound antibodies were detected by
horseradish peroxidase-conjugated (HRP) anti-rat IgG secondary anti-
body (Life Technologies) at a 1:10,000 dilution. Immunoreactive bands
were visualized by enhanced chemiluminescence (ECL) using a Super-
Signal West Pico chemiluminescent substrate kit (Pierce). The loading
control for the Western blot was performed with primary mouse anti-
ATP antibodies at a 1:5,000 dilution and a secondary anti-mouse IgG-
HRP antibody. For quantification of proteins on Western blots, the den-
sity of bands was measured using Image J 1.48v (National Institutes of
Health, USA; http://imagej.nih.gov/ij Java 1.6.0_65 [32-bit]). Protein ex-
pression levels were normalized to the loading control ATPase and re-
ported as relative density expressed in arbitrary units.
Statistical analysis. All results were expressed as the mean  standard
error of the mean. A comparison between the two groups was performed
using an unpaired Student t test. A P value of 0.05 was considered to
indicate a statistically significant difference. All statistical analyses were
performed using Graph Pad Prism version 7.0.
Immunofluorescence. Slides with intracellular parasites were pre-
pared by growing human foreskin fibroblast (HFF) cells on eight-well
glass Nunc Lab-Tek chamber slides (Thermo Scientific) for 24 h before
infection (30). HFF cells on slides were infected with fresh T. gondii cul-
ture (4 l) in invasion buffer (Eagle modified essential medium supple-
mented with 1% fetal bovine serum) and grown for 18 h. Parasites were
fixed with 1 Histochoice (Amresco) for 20 min at room temperature
(RT), permeabilized with 0.1% Triton X-100, blocked with 10% fetal
bovine serum (FBS)–1% normal goat serum (NGS)– 0.02% Triton-TX
solution, and stained with primary antibodies (Rb-HA, 1:400; Ms-
ATPase, 1:5,000; Ms-ATrx1, 1:5,000) and 4=,6-diamino-2-phenylindole
(DAPI) at 5 g/ml. Ms-ATPase (monoclonal antibody [MAb] 5F4 [47])
and Ms-ATrx1 (MAb 11G8 [48]) were kindly provided by Peter J. Brad-
ley (Department of Microbiology, Immunology and Molecular Genetics,
University of California, Los Angeles, CA, USA). Secondary goat anti-
mouse–Alexa-Fluor 594 and goat anti-rabbit–Alexa-Fluor 488 antibodies
(Molecular Probes/Invitrogen) were used at 1:1,000. Slides were mounted
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with Mowiol (Sigma) and examined on a Zeiss LSM 510 Meta laser-scan-
ning confocal microscope with a 63 oil objective. All images were col-
lected using the same settings for laser intensity, pinhole aperture, and
photomultiplier gain and offset. MitoTracker stain was used to examine
mitochondrial membrane potential. Parasite-infected cells were stained
with 100 nM MitoTracker Red (CMXRos; Life Technologies) in normal
growth medium (Dulbecco modified Eagle medium [DMEM] with 1%
Cosmic calf serum) for 30 min at 37°C, and then cultures were examined
for immunofluorescence as described above.
Expression and purification of N-terminally truncated wild-type
and mutant DHODHs. Wild-type T. gondii DHODH and mutant en-
zymes (N365A, N468A, and N365A/N468A) were overexpressed in BL21-
CodonPlus(DE3)RP cells (Stratagene) as previously described and puri-
fied as previously described with minor modifications (22). Briefly, cells
were resuspended in buffer A (2 mM beta-mercaptoethanol, 2% Triton
X-100, 10% glycerol, 0.5 mM riboflavin 5=-monophosphate [FMN], 300
mM NaCl, 50 mM Tris-HCl, pH 8.5) in the presence of 1 mM phenyl-
methylsulfonyl fluoride (PMSF), 1 mM benzamidine, and 1 mg/ml ly-
sozyme and incubated for 3 h on ice. After sonication and centrifugation,
recombinant proteins were purified using HisPur cobalt resin (Pierce)
equilibrated with buffer B (buffer A with 5 mM imidazole). The column
was washed with 15 mM imidazole, and proteins were eluted with 150
mM imidazole. Imidazole and excess FMN were removed using PD-10
desalting columns (Amersham) equilibrated with reaction buffer (150
mM KCl, 10% glycerol, 0.1% Triton, 50 mM Tris-HCl, pH 8.0). The
protein concentration was measured using the microplate procedure of
the bicinchoninic acid protein assay (Pierce) with bovine serum albumin
as the standard, using a Thermo Scientific Multiskan GO microplate spec-
trophotometer.
Enzyme activity assays. Activities of wild-type and mutant recombi-
nant TgDHODH enzymes were measured by monitoring 2,6-dichloro-
phenol-indophenol (DCIP) reduction as previously described (22). As-
says were performed in reaction buffer with 0.1 mM ubiquinone (QD) as
an electron acceptor and 0.1 mM DCIP. Dihydroorotate (DHO) concen-
trations were varied from 0.5 to 50 mM to obtain substrate saturation
curves. The following enzyme concentrations were used: 6.2 nM wild
type, 1.86 M N365A, 2.4 M N468A, and 2.4 M N365A/N468A. DCIP
reduction was measured at 600 nm (ε 	 18,800 M
1cm
1) during 120 s at
2-s intervals for the wild-type enzyme and single mutants. N365A/N468A
activity was measured for up to 10 min. All assays were performed in
triplicate, using a Beckman Coulter DU 800 UV/visible spectropho-
tometer.
Bioinformatics. Molecular graphics images were produced using the
UCSF Chimera package from the Resource for Biocomputing, Visualiza-
tion, and Informatics at the University of California, San Francisco (http:
//www.cgl.ucsf.edu/chimera/). The Escherichia coli protein structure
identified with the number PDB:1F76 was used for modeling.
RESULTS
Design of mutant TgDHODH enzymes. DHODH oxidizes dihy-
droorotate to orotate with coordinate reduction of the enzyme-
bound FMN in a stepwise reaction. Site-directed mutagenesis of
several conserved asparagine (N) residues in E. coli DHODH ad-
versely affected substrate or product binding as well as reduction
rate constants (31). Mutation of N172 of E. coli DHODH caused a
large decrease in the reduction rate constant with a slight decrease
in dihydroorotate affinity, while mutation of N246 caused a large
decrease in both kinetic parameters (31). Examination of the E.
coli DHODH crystallographic structure shows that residues N172
and N246 are predicted to establish three hydrogen bonds with
orotate (Fig. 1A) (20, 31). The N172A mutation abolishes one of
these hydrogen bonds (Fig. 1B), the N246A mutation abolishes
two of these hydrogen bonds (Fig. 1C), and the double mutation
(DM) abolishes all three of these hydrogen bonds (Fig. 1D).
We identified the conserved residues corresponding to E. coli
DHODH N172 and N246 in TgDHODH as N365 and N468 from
previously reported ClustalW alignments of various DHODH
proteins (22), and we hypothesized that mutation of either N365
or N468 in TgDHODH would ablate enzyme activity.
Kinetic parameters of mutant TgDHODH enzymes. Using a
cDNA that expresses active N-terminally truncated wild-type
TgDHODH enzyme (22), we constructed three mutant TgDHODH
enzymes, N365A, N468A, and a N365A/N468A double mutant
(DM). The bacterial expression vector pET19b was used to pro-
duce recombinant TgDHODH proteins. Purified recombinant
proteins of wild-type TgDHODH or mutant enzymes were frac-
tionated on SDS gels. As expected, the molecular mass observed
for all the recombinants remained the same as that of the wild-
type enzyme (45 kDa) (Fig. 2A). Dihydroorotate oxidation was
measured in the presence of the artificial electron acceptor QD
using purified wild-type or mutant enzymes. The N365A and
N468A mutants showed significant increases in Km and significant
decreases in kcat (Fig. 2B and C). The kinetic efficiencies (kcat/Km)
of the N365A and N468A mutant enzymes were reduced by 1,644-
fold and by 296,000-fold, respectively, in comparison to that of the
wild-type enzyme (Fig. 2C). Moreover, no detectable enzyme ac-
tivity was observed for the DM enzyme. Attempts to obtain a
detectable activity for the DM by increasing enzyme and substrate
concentrations were unsuccessful. These results correlate with de-
fects in kinetic parameters previously observed in the correspond-
ing mutant E. coli DHODH enzymes (31), reinforcing the critical
FIG 1 Views of the orotate binding site in wild-type and mutant E. coli DHODHs. The E. coli DHODH crystallographic structure (PDB ID: 1F76) was used to
illustrate hydrogen bond interactions of orotate (green) with residues within 5 Å. (A) Hydrogen bonds predicted to form are shown in the wild-type enzyme. (B
to D) Arrows indicate hydrogen bonds that are predicted to lose contact with orotate in enzymes with the single mutation N172A (B) or N246A (C) or in the
N172A/N246A double mutant (D).
Hortua Triana et al.
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importance of these asparagine residues in stabilizing the pyrim-
idine for efficient catalytic activity of family 2 DHODH enzymes.
Replacing the endogenous TgDHODH gene with mutant
gene alleles. Several efforts to delete the TgDHODH gene were
unsuccessful (22). However, the TgDHODH gene is not refractory
to gene targeting, since this gene was successfully targeted at
its chromosomal locus to generate a C-terminally HA-tagged
TgDHODH to demonstrate mitochondrial localization of
TgDHODH (22). Together, these results suggested that the TgDHODH
protein could have a second essential function in the mitochondria
that is independent of its predicted role in T. gondii pyrimidine
biosynthesis. We hypothesized that expression of a TgDHODH
protein deficient in enzyme activity and simultaneous deletion
of the endogenous TgDHODH gene may enable the rescue of
the unknown second mitochondrial function of TgDHODH,
creating a mutant phenotype of uracil auxotrophy that can be
rescued in vitro by supplementation of the growth medium
with uracil.
The wild-type TgDHODH or the engineered single mutant or
double mutant gene alleles, all C-terminally tagged with HA, were
targeted to the endogenous TgDHODH gene locus to simultane-
ously delete and replace the endogenous TgDHODH gene. The
strategy for gene replacement used previously engineered plas-
mids expressing the recombinant TgDHODH proteins (Fig. 2);
however, integration of the targeting plasmid at the TgDHODH
gene locus was designed to rescue the complete coding region of
TgDHODH or the mutant enzymes (Fig. 3A). Progeny were se-
lected in mycophenolic acid plus xanthine plus uracil. Several
progeny with the correct genotype of the targeted gene replace-
ment were validated using a PCR strategy to demonstrate correct
5= and 3= integration of the 5= and 3= target DNA flanks carried on
the targeting plasmid (PCR4 and PCR5), the presence of the plas-
mid-targeted TgDHODH gene in the endogenous TgDHODH
chromosomal locus (PCR2B* and PCR4), and the absence of the
endogenous TgDHODH gene (PCR1, PCR2A, and PCR3) (Fig. 3B
and C). In addition, Western blots using anti-HA antibody
demonstrated expression of the HA-tagged TgDHODH prod-
ucts from the wild type, the single mutants, or the DM (Fig.
4A). Relative to the ATPase control, expression of the DM was
reduced in comparison to those of N468A and the wild-type
TgDHODH (Fig. 4B).
FIG 2 Kinetic parameters of wild-type and mutant T. gondii DHODH
enzymes. (A) SDS-PAGE showing the purified wild-type and mutant
TgDHODHs. (B) Dihydroorotate saturation curves of purified TgDHODH
mutants N365A (closed circles) and N468A (open circles). The concentration
of QD was fixed at 0.1 mM, while the concentration of dihydroorotate was
varied from 0 to 40 mM. Measurements for each point were in triplicate, and
the background activity in the absence of enzyme was subtracted. (C) Michae-
lis constants, turnover numbers, and specificity constants for TgDHODH ac-
tive-site mutants and the wild-type enzyme.
FIG 3 Gene replacements at the endogenous TgDHODH gene locus. (A) Top,
gene-targeting plasmids were engineered to contain the 5= DHODH target
flank, the wild-type or mutant TgDHODH gene containing a C-terminal HA
tag, the HXGPRT selectable marker, and the 3=DHODH target flank. Bottom,
the endogenous TgDHODH gene (light and dark gray box) was targeted for
gene replacement using linearized targeting plasmid. The 12 coding exons in
the endogenous gene are shown by white numbers (1 to 12). The N terminus
(exon 1 and intron 1), missing in the targeting plasmid constructs, was rescued
by correct integration into the endogenous TgDHODH gene locus following
selection in mycophenolic acid (MPA) plus xanthine plus uracil. (B) Sche-
matic representation of the PCR genotype validation scheme. Approximate
locations of PCR products used to validate genotypes are shown. (C) Repre-
sentative clones showing correct gene replacements for N365A, N468A, DM,
and wild-type TgDHODHs. Strains with correct integration of the mutated
DHODH construct were positive only for PCR2B (300 bp). The parental strain
RH ku80 hxgprt (endogenous TgDHODH gene locus) was positive for
PCR1 (480 bp) and PCR2 (800 bp). The lack of PCR amplification observed for
PCR3 confirms excision of the endogenous gene. (D) Representative clones
showing correct gene replacements for N365A, N468A, DM, and wild-type
TgDHODHs. Strains with correct 5= integration (PCR4, 1,780 bp) and 3= in-
tegration (PCR5, 1,220 bp) are shown. Lanes: M, standard size markers; 
,
negative control; P, parental strain; 1 to 6, clones tested per strain.
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Wild-type and mutant TgDHODH enzymes localize to the
parasite mitochondria. TgDHODH localizes to mitochondria
(22). The T. gondii strains carrying wild-type or mutant DHODH
gene replacements at the endogenous TgDHODH locus were eval-
uated to examine the cellular localization of TgDHODH. As ex-
pected, HA-tagged TgDHODH colocalized with the mitochon-
drial marker ATPase (Fig. 5A) and was not localized with the
apicoplast marker ATrx1 (Fig. 5B), showing correct localization of
the mutant enzymes to the mitochondrion.
Enzyme activity-deficient TgDHODH mutants are uracil
auxotrophs. To determine if ablation of DHODH activity in-
duced pyrimidine auxotrophy, the mutant or wild-type strains
were subjected to plaque assays in the presence or absence of uracil
supplementation. The strain with the catalytically active wild-type
TgDHODH gene allele replicated to form plaques with or without
uracil supplementation. In contrast, the single mutant strains as well
as the DM strain were uracil auxotrophs and did not replicate to
develop plaques in the absence of uracil supplementation (Fig. 6).
Mutant TgDHODH strains contain active mitochondria.
MitoTracker Red CMXRos is an indicator that stains mitochon-
dria in living cells, and staining depends on the presence of a
functional membrane potential (32). Wild-type and mutant strains
were cultured in the presence of uracil to obtain intracellular parasite
vacuoles, and vacuoles were stained with MitoTracker to examine
whether fluorescence was associated with parasite mitochondria. T.
gondii actively recruits host cell mitochondria to the surface mem-
brane of the parasitophorous vacuole (PVM) (33); consequently,
MitoTracker will stain host mitochondria associated with the
PVM as well as parasite mitochondria associated with each
tachyzoite inside the vacuole. MitoTracker stained both parasite
and host mitochondria, and the staining patterns were identical in
the wild-type and mutant DHODH strains (Fig. 7), suggesting
that inactivation of the TgDHODH enzyme activity did not sig-
nificantly affect the membrane potential of parasite mitochondria
or PVM-associated host mitochondria (Fig. 7).
DISCUSSION
Pyrimidine biosynthesis is an essential pathway in T. gondii. Pre-
vious genetic studies in T. gondii have shown that deletion of the
gene(s) encoding the first, fifth, or sixth steps of the pyrimidine
biosynthetic pathway in T. gondii induced uracil auxotrophy and
virulence attenuation and abolished chronic infection of the host
(16–19), suggesting that inhibitors of TgDHODH could be active
FIG 4 Tachyzoites of T. gondii express mutated DHODHs. (A) Western blot-
ting was performed using lysed tachyzoites from endogenously HA-tagged
wild-type (WT), N365A, N468A, and DM strains. The parental strain was used
as a negative control. Anti-HA antibodies (top) recognize a band of 50 kDa
in the three TgDHODH mutants and the wild-type TgDHODH but not in the
nontagged parental strain. The mitochondrial marker ATP synthase (anti-
ATPase antibodies) (bottom) was used as a standard for sample loading. (B)
Relative expression level of TgDHODH compared to ATPase. Three replicate
Western blots were analyzed using ATPase as the standard for expression level.
Protein expression level is reported as relative density and is expressed in
arbitrary units. Values are means  standard errors of the means (SEM). ****,
P  0.0001 for VSSM versus DM; *, P  0.05 for N468A versus DM.
FIG 5 Subcellular localization of mutant TgDHODH enzymes. (A) Intracel-
lular tachyzoites expressing mutant HA-tagged TgDHODH were used in dou-
ble-staining immunofluorescence with anti-HA (green) and the mitochon-
drial marker ATP synthase (anti-ATPase) (red). Nuclei were stained with
DAPI (blue). Yellow arrows show colocalization of mutant or wild-type (WT)
TgDHODH with mitochondrial ATP synthase (merge panel). (B) Staining
immunofluorescence using antibodies against HA (anti-HA) (green) and the
apicoplast marker ATrx1 (anti-ATrx1) (red). Nuclei were stained with DAPI
(blue). White arrows show no colocalization of HA with ATrx1.
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against both acute and chronic stages of infection. However, at-
tempts to directly delete the TgDHODH gene were unsuccessful.
Here, we show that replacement of the endogenous TgDHODH
gene with a catalytically deficient mutant TgDHODH gene allele
was sufficient to establish uracil auxotrophy. These findings show
that TgDHODH is essential for the synthesis of pyrimidines and
participates in another essential mitochondrial function that is
not directly dependent on TgDHODH enzyme activity in the py-
rimidine biosynthetic pathway.
The enzyme activity of DHODH has been a highly investigated
target for the development of inhibitors used to treat autoimmune
diseases and for their use in treatments for cancer and virus and
parasitic infections (34). In particular, significant progress has
been made in identifying clinically relevant inhibitors of the Plas-
modium DHODH that show promise for further clinical develop-
ment in malaria treatment (10, 11). We have previously reported
an initial screen of potential inhibitors of TgDHODH, and several
micromolar inhibitors were identified (22). However, the search
for inhibitors of the T. gondii enzyme has been hindered by the
absence of a crystal structure for this enzyme. Our results using
mutagenesis and protein expression assays confirm the predicted
active-site residues of the TgDHODH. The N365A mutation in-
creased the Km for dihydroorotate and severely reduced the kcat,
while the N468A mutation severely affected both kinetic parame-
ters. Enzyme activity was not detected in the double mutant.
Overall, these impaired kinetic properties of TgDHODH activity
are consistent with previous mutagenesis studies performed on
corresponding mutations developed in the E. coli DHODH (31)
and reinforce the importance of these key asparagine residues in
catalysis. TgDHODH differs from other family 2 DHODHs in
containing an extended N-terminal targeting sequence of 157
amino acids that appears to be cleaved during mitochondrial im-
port (22). In contrast, the human HsDHODH contains only a
short N-terminal sequence (13 amino acid residues) that is not
removed (21). TgDHODH also displays an internal insertion of
approximately 20 to 30 amino acid residues, a novel characteristic
FIG 6 Catalytically deficient mutant TgDHODH strains are uracil auxo-
trophs. The wild-type (WT) strain and three catalytically deficient TgDHODH
mutant strains (N365A, N468A, and DM) were grown in the absence (left) or
in the presence (right) of uracil supplementation, and plaques were measured
7 days later. Uracil auxotrophy was observed in the mutants.
FIG 7 Catalytically deficient mutant TgDHODH strains contain active mitochondria. MitoTracker retention in the mitochondria (red) was tested on nonfixed
intracellular wild-type (WT) or mutant TgDHODH parasites. TgDHODH was localized with anti-HA antibody (green). Nuclei were stained with DAPI (blue).
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that it shares with Plasmodium DHODH enzymes (22). However,
this insertion in the Plasmodium DHODH was not required for
catalytic activity (35). It remains to be examined whether this
novel insertion is required for the pyrimidine-independent role of
TgDHODH.
Our results confirm the expected essential enzyme activity of
TgDHODH in pyrimidine biosynthesis and point to the presence
of a second essential function for TgDHODH that is independent
of the enzyme activity. Pyrimidine biosynthesis is coupled to the
respiratory chain by the participation of ubiquinone in the reoxi-
dation of DHODH, and the electrons generated from dihydrooro-
tate oxidation are transferred into the respiratory chain (24). T.
gondii and blood stages of malaria parasites both require mitochon-
drial metabolism, because these parasites are highly susceptible to
inhibitors of cytochrome bc1 (complex III), such as atovaquone (36–
38), that inhibit electron transport through the essential respira-
tory chain (39–41). Recent studies on mammalian DHODH have
shown that DHODH is physically associated with the respiratory
chain complexes III and II (42). Moreover, depletion of DHODH
induced cell cycle arrest and mitochondrial dysfunction (42–44).
Here, we show that wild-type and mutant TgDHODH enzymes
localized to the parasite mitochondria and that T. gondii express-
ing catalytically deficient DHODH retained an intact mitochon-
drial membrane potential even with reduced expression levels of
catalytically deficient TgDHODH enzymes. These observations
suggest that the pyrimidine biosynthetic function of TgDHODH
is not strictly required for maintaining the essential respiratory
chain in T. gondii, though our results should be interpreted cau-
tiously because MitoTracker staining may not reveal a reduced
membrane potential in contrast to a collapsed membrane poten-
tial. Collectively, our findings point to a novel and essential role
for TgDHODH in mitochondrial function and physiology that is
independent of pyrimidine biosynthesis. These findings are im-
portant for future drug development because they suggest that
inhibitors of the TgDHODH molecule could block an essential
enzymatic step in pyrimidine biosynthesis as well as block an es-
sential function of TgDHODH in mitochondrial physiology.
Identifying selective inhibitors of TgDHODH as well as the mo-
lecular basis of the pyrimidine-independent role for TgDHODH
merits further investigation.
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